Clinical Trial Details
| Trial ID: | L3872 |
| Source ID: | NCT04470310 |
| Associated Drug: | Glimepiride |
| Title: | Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination |
| Acronym: | |
| Status: | UNKNOWN |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes Mellitus |
| Interventions: | DRUG: Glimepiride|DRUG: Alogliptin 25Mg Tab|DRUG: Alogliptin-Pioglitazone 25 Mg-15 Mg Oral Tablet |
| Outcome Measures: | Primary: HbA1c, The change in the mean level of HbA1c from baseline at week 24, Baseline, Week 24 | Secondary: HbA1c and fasting plasma glucose, The change in the mean level of HbA1c at week 12 and mean FPG( fasting plasma glucose) levels, Baseline, Week 12, Week 24|The change in parameters of glycemic variability assessed by CGM from the Baseline at week 24, The change in parameters of glycemic variability assessed by CGM from baseline at week 24: SD(standard deviation), MAGE(Mean Amplitude of Glycaemic Excursions); MODD(Mean of Daily Differences); ADDR(Average Daily Risk Range), M-value, Baseline, Week 24|The change in lipid profile from baseline at week 12 and 24, The average change in the lipid profile: Total cholesterol (mg/dL), Triglyceride(mg/dL), HDL-cholesterol, (mg/dL) LDL cholesterol (mg/dL), Baseline, Week 12, Week 24 |
| Sponsor/Collaborators: | Sponsor: Seoul National University Hospital |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 99 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2015-12-31 |
| Completion Date: | 2021-08-31 |
| Results First Posted: | |
| Last Update Posted: | 2020-10-22 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT04470310 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|